Percutaneously coronary intervention (PCI) on coronary artery lipid-rich plaque detected by near infrared spectroscopy was not associated with subsequent major adverse cardiac events compared to PCI of non-lipid-rich plaque, according to the results of the COLOR Trial presented Nov. 1 at TCT 2016.

In a prospective, multicenter, observational study, Giora Weisz, MD, FACC, et al., assessed the outcomes after PCI of lipid-rich protein detected by near infrared spectroscopy. A total of 1,899 patients at 22 sites in the U.S. underwent near infrared spectroscopy during a clinically indicated catheterization procedure. The primary endpoint was the occurrence of major adverse cardiac events – a composite of cardiac death, myocardial infarction, stent thrombosis, revascularization and hospitalization – at two years.

The results of the study showed that non-culprit lesion related events were slightly more common than culprit lesion post-PCI related events during two-year follow-up. The overall rate of major adverse cardiac events at two years was 14.1 percent for all patients – 6 percent related to the culprit lesion, 8.3 percent related to the non-culprit lesion and 2.4 percent indeterminate.

According to Weisz, “the results also indicate that PCI of near infrared spectroscopy-defined lipid-rich plaques was safe and was not associated with increased peri-procedural or long-term adverse outcomes compared to PCI of non-lipid-rich plaques. Additional studies are needed to determine the clinical significance of near infrared spectroscopy-defined non-culprit lipid-rich plaques.”

Keywords: Transcatheter Cardiovascular Therapeutics, Angina, Stable, Coronary Artery Disease, Lipids, Plaque, Atherosclerotic, Registries, Stents, Catheterization, Coronary Vessels, Follow-Up Studies, Hospitalization, Myocardial Infarction, Percutaneous Coronary Intervention, Prospective Studies, Spectroscopy, Near-Infrared, Thrombosis

< Back to Listings